These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Alpha 1-antitrypsin deficiency and the impact of nursing interventions and treatment with intravenous therapy. An overview. Scharnweber K J Intraven Nurs; 1999; 22(5):258-64. PubMed ID: 10776189 [TBL] [Abstract][Full Text] [Related]
8. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group. Gottlieb DJ; Luisetti M; Stone PJ; Allegra L; Cantey-Kiser JM; Grassi C; Snider GL Am J Respir Crit Care Med; 2000 Dec; 162(6):2069-72. PubMed ID: 11112116 [TBL] [Abstract][Full Text] [Related]
9. Key current clinical issues in alpha-1 antitrypsin deficiency. Stoller JK Respir Care; 2003 Dec; 48(12):1216-21; discussion 1221-4. PubMed ID: 14651762 [TBL] [Abstract][Full Text] [Related]
10. Severe ulcerative panniculitis caused by alpha 1-antitrypsin deficiency: remission induced and maintained with intravenous alpha 1-antitrypsin. Al-Niaimi F; Lyon C J Am Acad Dermatol; 2011 Jul; 65(1):227-9. PubMed ID: 21679830 [No Abstract] [Full Text] [Related]
11. [Hereditary alpha-1-antitrypsin deficiency can cause COPD. Substitution treatment seems to result in fewer infections and prolonged survival]. Janciauskiene S Lakartidningen; 2007 Nov 28-Dec 4; 104(48):3631-4, 3637-8. PubMed ID: 18193673 [No Abstract] [Full Text] [Related]
12. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency. Tirado-Conde G; Lara B; Miravitlles M Ther Adv Respir Dis; 2008 Feb; 2(1):13-21. PubMed ID: 19124355 [TBL] [Abstract][Full Text] [Related]
13. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Schluchter MD; Stoller JK; Barker AF; Buist AS; Crystal RG; Donohue JF; Fallat RJ; Turino GM; Vreim CE; Wu MC Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):796-801. PubMed ID: 10712324 [TBL] [Abstract][Full Text] [Related]
14. Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration. Barker AF; Siemsen F; Pasley D; D'Silva R; Buist AS Chest; 1994 May; 105(5):1406-10. PubMed ID: 8181327 [TBL] [Abstract][Full Text] [Related]
16. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency. Louie SG; Sclar DA; Gill MA Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903 [TBL] [Abstract][Full Text] [Related]
18. Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. Monk R; Graves M; Williams P; Strange C COPD; 2013 Aug; 10(4):411-5. PubMed ID: 23537112 [TBL] [Abstract][Full Text] [Related]
19. Alpha1-antitrypsin deficiency-associated panniculitis: case report and review of treatment options. Ortiz PG; Skov BG; Benfeldt E J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):487-90. PubMed ID: 15987301 [TBL] [Abstract][Full Text] [Related]
20. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Bergin DA; Hurley K; McElvaney NG; Reeves EP Arch Immunol Ther Exp (Warsz); 2012 Apr; 60(2):81-97. PubMed ID: 22349104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]